share_log

424B5: Prospectus

424B5: Prospectus

424B5：募资说明书
美股SEC公告 ·  11/04 17:24

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals has announced a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of common stock with an aggregate offering price of up to $3,556,586. The sales may occur from time to time through A.G.P., acting as the sales agent or principal. Conduit Pharmaceuticals, an emerging growth company listed under the symbol 'CDT' on the Nasdaq Global Market, plans to use the initial proceeds to repay approximately $600,000 in principal from a Bridge Loan Agreement with A.G.P. The company's common stock last traded at $0.091 per share as of October 31, 2024. This move is part of Conduit Pharmaceuticals' efforts to raise capital for working capital and general corporate purposes, including the development of their clinical assets targeting a range of autoimmune disorders.
Conduit Pharmaceuticals has announced a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of common stock with an aggregate offering price of up to $3,556,586. The sales may occur from time to time through A.G.P., acting as the sales agent or principal. Conduit Pharmaceuticals, an emerging growth company listed under the symbol 'CDT' on the Nasdaq Global Market, plans to use the initial proceeds to repay approximately $600,000 in principal from a Bridge Loan Agreement with A.G.P. The company's common stock last traded at $0.091 per share as of October 31, 2024. This move is part of Conduit Pharmaceuticals' efforts to raise capital for working capital and general corporate purposes, including the development of their clinical assets targeting a range of autoimmune disorders.
Conduit Pharmaceuticals宣布与A.G.P./全球合作伙伴达成销售协议，以提供并出售普通股，合计最高价为$3,556,586。销售可能不时通过A.G.P.作为销售代理或负责人进行。作为新兴增长公司的Conduit Pharmaceuticals，在纳斯达克全球市场上以“CDT”标的上市，计划使用最初收入偿还与A.G.P.的桥梁贷款协议约$600,000的本金。截止2024年10月31日，公司的普通股最近以每股$0.091交易。这一举措是Conduit Pharmaceuticals为筹集用于营运资金和一般公司用途的资本而进行的努力，包括开发其面向一系列自身免疫紊乱的临床资产。
Conduit Pharmaceuticals宣布与A.G.P./全球合作伙伴达成销售协议，以提供并出售普通股，合计最高价为$3,556,586。销售可能不时通过A.G.P.作为销售代理或负责人进行。作为新兴增长公司的Conduit Pharmaceuticals，在纳斯达克全球市场上以“CDT”标的上市，计划使用最初收入偿还与A.G.P.的桥梁贷款协议约$600,000的本金。截止2024年10月31日，公司的普通股最近以每股$0.091交易。这一举措是Conduit Pharmaceuticals为筹集用于营运资金和一般公司用途的资本而进行的努力，包括开发其面向一系列自身免疫紊乱的临床资产。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间